Efektivitas Efepoetin Alfa dalam Mengatasi Anemia yang Disebabkan oleh Kemoterapi pada Pasien Kanker Payudara: Serangkaian Kasus
Laporan Kasus
DOI:
https://doi.org/10.55175/cdk.v52i12.1973Kata Kunci:
Anemia, kanker payudara, serial kasus, anemia yang diinduksi kemoterapi, efepoetin alfaAbstrak
Pendahuluan: Anemia merupakan komplikasi umum pada pasien kanker dan secara signifikan mengurangi kualitas hidup melalui gejala seperti kelelahan dan gangguan kognitif. Kasus ini mengevaluasi penggunaan efepoetin alfa untuk mengobati anemia yang disebabkan oleh kemoterapi pada pasien kanker payudara stadium lanjut di Indonesia. Kasus: Enam wanita Asia berusia 43–59 tahun dengan kanker payudara stadium III yang menerima kemoterapi docetaxel-doxorubicin mengalami anemia sedang (rata-rata hemoglobin [Hb] baseline 9,5 g/dL). Pasien menerima efepoetin alfa subkutan (umumnya 0,3 mg/0,3 mL sekali); Hb dievaluasi ulang rata-rata 8 hari setelah suntikan terakhir. Diskusi: Rata-rata Hb pasca-perawatan naik menjadi 12,1 g/dL (rata-rata ΔHb ≈ 2,6 g/dL). Tidak ada kejadian efek samping serius yang diamati selama masa tindak lanjut singkat. Simpulan: Dalam kasus ini, efepoetin alfa terkait dengan peningkatan cepat Hb dan perbaikan hasil yang dilaporkan pasien; namun, studi konfirmasi yang lebih besar, dosis dan pemantauan yang terstandarisasi, serta masa tindak lanjut yang lebih lama diperlukan untuk mendefinisikan efektivitas dan keamanan jangka panjang.
Unduhan
Referensi
Natalucci V, Virgili E, Calcagnoli F, Valli G, Agostini D, Zeppa SD, et al. Cancer related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients 2021;13(2):482. doi: 10.3390/nu13020482.
Muthanna FMS, Karuppannan M, Abdulrahman E, Uitrakul S, Rasool BAH, Mohammed AH. Prevalence and associated factors of anemia among breast cancer patients undergoing chemotherapy: a prospective study. Adv Pharmacol Pharm Sci. 2022;2022:7611733. doi:10.1155/2022/7611733.
Sharma P, Georgy JT, Andrews AG, John AO, Joel A, Chacko RT, et al. Anemia requiring transfusion in breast cancer patients on dosedense chemotherapy: prevalence, risk factors, cost and effect on disease outcome. Support Care Cancer 2022;30(6):5519−26. doi:10.1007/s00520-022-06970-2.
Gvirtzman R, Livovsky DM, Tahover E, Goldin E, Koslowsky B. Anemia can predict the prognosis of colorectal cancer in the preoperative stage: a retrospective analysis. World J Surg Oncol. 2021;19(1):341. doi: 10.1186/s12957-021-02452-7.
Ackfeld T, Schmutz T, Guechi Y, Le Terrier C. Blood transfusion reactions-a comprehensive review of the literature including a Swiss perspective. J Clin Med. 2022;11(10):2859. doi: 10.3390/jcm11102859.
Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336−51. doi: 10.1200/JCO.18.02142.
Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascon P, Glaspy J, et al. ESMO guidelines committee. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018 1;29(Suppl 4):iv96-iv110. doi: 10.1093/annonc/ mdx758. Erratum in: Ann Oncol. 2018;29(Suppl 4):iv271. doi: 10.1093/annonc/mdy323.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, et al. NCCN guidelines® insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw. 2022;20(5):436−2. doi: 10.6004/jnccn.2022.0026.
Escobar Alvarez Y, de Las Penas Bataller R, Perez Altozano J, Ros Martínez S, Sabino Álvarez A, Blasco Cordellat A, et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931−9. doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192−3. doi: 10.1007/s12094-021-02681-y.
KGBio. Efesa phase II clinical study report. Jakarta: Kalbe Genexine Biologic; 2016.
Riley DS, Barber MS, Kienle GS, AronsonJK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017 May 18. pii: S0895-4356(17)30037−9. https://doi.org/10.1016/j.jclinepi.2017.04.026.
Rodgers GM III, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw, 2012;10(5):628−53. https://doi.org/10.6004/jnccn.2012.0064.
Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol. 2001;28(2 Suppl 8):15–8. doi: 10.1016/s0093-7754(01)90207-6.
Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010–2013. Clin Epidemiol. 2016;8:61−71. doi: 10.2147/CLEP.S89480.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5.
Gergal Gopalkrishna Rao SR, Bugazia S, Dhandapani TPM, Tara A, Garg I, Patel JN, et al. Efficacy and cardiovascular adverse effects of erythropoiesis stimulating agents in the treatment of cancer-related anemia: a systematic review of randomized controlled trials. Cureus 2021;13(9):e17835. doi: 10.7759/cureus.17835.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2025 Zainal Abidin, Anova Fatimah
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
